(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride

(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride Suppliers list
Company Name: 3B Pharmachem (Wuhan) International Co.,Ltd.  
Tel: 18930552037
Email: 3bsc@sina.com
Company Name: Shanghai JiYi Biotechnology Co. Ltd.  
Tel: 13621943973
Email: sales@shjiyipharmatech.com
Company Name: Shanghai Lollane Biological Technology Co.,Ltd.  
Tel: 021-52996696,15000506266 15000506266
Email:
Company Name: EMMX Biotechnology LLC  
Tel: 888-539-0666
Email: info@emmx.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride Basic information
Product Name:(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride
Synonyms:(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride;TCS OX2 29;(2S)-1-(6,7-DIMETHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-3,3-DIMETHYL-2-(PYRIDIN-4-YLMETHYLAMINO)BUTAN-1-ONE;TCS-OX2-29, CID 10408514;1-Butanone, 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-, (2S)-;(S)-1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3,3-dimethyl-2-((pyridin-4-ylmethyl)amino)butan-1-one;TCS OX2 29, Orexin-2 receptor antagonist;TCS-OX2-29, 10 mM in DMSO
CAS:372523-75-6
MF:C23H31N3O3
MW:397.51
EINECS:
Product Categories:
Mol File:372523-75-6.mol
(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride Structure
(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride Chemical Properties
storage temp. Keep in dark place,Inert atmosphere,2-8°C
solubility DMSO : 25 mg/mL (62.89 mM; Need ultrasonic)Ethanol : 25 mg/mL (62.89 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
form Powder
color White to off-white
Water Solubility H2O: ≥2.0mg/mL, clear
InChI1S/C23H31N3O3/c1-23(2,3)21(25-14-16-6-9-24-10-7-16)22(27)26-11-8-17-12-19(28-4)20(29-5)13-18(17)15-26/h6-7,9-10,12-13,21,25H,8,11,14-15H2,1-5H3/t21-/m1/s1
InChIKeyCOFVZFLCAOUMJT-OAQYLSRUSA-N
SMILESN2(CCc3c(cc(c(c3)OC)OC)C2)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C
Safety Information
WGK Germany WGK 3
Storage Class11 - Combustible Solids
MSDS Information
(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride Usage And Synthesis
UsesTCS OX2 29 is a potent and selective orexin-2 receptor (OX2) antagonist.
Biological ActivityTCS OX2 29 or TCS-OX2-29 is a potent and selective orexin 2 receptor (Ox2R, Ox2-R, Ox-2-R) antagonist (IC50 = 40 nM/Ox2R, >10 μM/Ox1R) with little potency toward 50 other receptors, ion channels, and transporters tested (<30% inhibition at 10 μM). TCS OX2 29 is widely used for elucidating various physiological functions mediated by Ox2R both in cultures and in mice and rats in vivo.
in vivo

TCS-OX2-29 (5-10 mg/kg; intraperitoneal injection; adult male NMRI mice) treatment suppresses conditioned place preference (CPP) acquisition and expression in both na ve and dependent mice significantly[2].

Animal Model:440 adult male NMRI mice (25-30 g)[2]
Dosage:5 mg/kg and 10 mg/kg
Administration:Intraperitoneal injection (Pharmacokinetic study)
Result:Suppressed conditioned place preference (CPP) acquisition and expression in both nave and dependent mice significantly.
IC 50OX2 Receptor
(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride Preparation Products And Raw materials
Tag:(2S)-1-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-[(4-pyridinylmethyl)amino]-1-butanonehydrochloride(372523-75-6) Related Product Information
Orexin 2 Receptor Agonist Rocatinlimab N-(2-Methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea Orexin A (17-33) MK 6096 Vonlerolizumab